Akums Drugs and Pharmaceuticals Ltd (AKUMS) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Revenue from the $25 million Zambia government contract will be booked in Q1 FY28, as dispatches in Q4 FY27 face a 100-120 day shipping timeline.
- The new Baddi facility's first phase, adding 6 billion units of capacity, will be operational by Q1 FY28 to support sustained CDMO volume growth.
- Management confirmed no financial liability or provision has been made for the NPPA show-cause notice, citing contractual protection with its marketing partner.
Performance Overview
- Akums Drugs and Pharmaceuticals Ltd delivered a strong performance in Q2 FY27, driven by double-digit volume growth and a robust order book.
- The company reported significant year-on-year growth, with revenue increasing by over 30% and EBITDA more than doubling.
- Successful integration of two manufacturing plants acquired from Oriflame has strengthened the company's position in the beauty and personal care category.
- The core CDMO business demonstrated resilience with over 20% volume growth, operating at healthy utilization levels of above 50%.
- Strategic initiatives are progressing, including the operationalization of a new facility in Baddi and advancements in European and Zambian CDMO projects.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.